Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833211 | 0.85 | ALDH1A1 (0.47) | MEN1KMT2ANPSR1LMNATSHR | |
| SCHEMBL965398 | 0.84 | MEN1 (0.47) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL4842800 | 0.83 | RORC (0.44) | KMT2ANPSR1LMNATSHRGAA | |
| SCHEMBL926085 | 0.80 | LMNA (0.50) | MEN1KMT2ANPSR1POLBLMNA | |
| SCHEMBL3591921 | 0.80 | LMNA (0.50) | MEN1KMT2ANPSR1POLBLMNA | |
| SCHEMBL4837892 | 0.79 | GHSR (0.41) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4833643 | 0.79 | GHSR (0.41) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4832819 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4836363 | 0.77 | MMP2 (0.41) | MEN1KMT2APOLBLMNATSHR | |
| SCHEMBL4843043 | 0.76 | ALDH1A1 (0.47) | MEN1KMT2ANPSR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | MEN1 4595/4885KMT2A 2387/4885NPSR1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.